Introduction: Long-acting bronchodilators are pivotal in the therapeutic management of COPD patients with moderate-to-severe airflow obstruction. New ultra-long-acting β2-agnoists (ultra-LABAs) have been developed, some of which have been licensed for use as monotherapy and/or in combination with other bronchodilators or inhaled corticosteroids, for use in COPD patients with persistent symptoms and worsening airflow limitation. These new agents are faster in onset and have a prolonged duration of action, with a similar safety profile to the traditional twice-daily bronchodilators which may have an impact on patient concordance. Areas covered: A number of these ultra-LABAs are still under development and bi-functional hybrid molecules contai...
An important step in simplifying asthma and chronic obstructive pulmonary disease (COPD) management ...
Abstract Chronic obstructive pulmonary disease (COPD) represents a significant cause of global morbi...
Introduction Long-acting muscarinic receptor antagonist (LAMA)/beta(2)-agonist (LABA) combinations r...
Chronic obstructive pulmonary disease (COPD) is characterised by progressive airflow limitation. In ...
Introduction: Bronchodilators are the cornerstone of chronic obstructive pulmonary disease (COPD) th...
Abstract Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow limita...
Inhaled bronchodilators, including long-acting muscarinic receptor antagonists (LAMA) and long-actin...
Combining a long-acting β2-agonist (LABA) with a long-acting anti-muscarinic agent (LAMA) provides s...
Bronchodilators are the cornerstone of pharmacological management of COPD. For patients whose condit...
Despite the passionate debate over the use of β(2) -adrenoceptor agonists in the treatment of airway...
Josuel Ora,1 Angelo Coppola,2 Mario Cazzola,3 Luigino Calzetta,4 Paola Rogliani1,3 1Division of Resp...
Inhaled bronchodilators, including beta2-agonists and antimuscaric receptor antagonists, are the mai...
Inhaled bronchodilators, including beta2-agonists and antimuscaric receptor antagonists, are the mai...
An important step in simplifying asthma and chronic obstructive pulmonary disease (COPD) management ...
Abstract Chronic obstructive pulmonary disease (COPD) represents a significant cause of global morbi...
Introduction Long-acting muscarinic receptor antagonist (LAMA)/beta(2)-agonist (LABA) combinations r...
Chronic obstructive pulmonary disease (COPD) is characterised by progressive airflow limitation. In ...
Introduction: Bronchodilators are the cornerstone of chronic obstructive pulmonary disease (COPD) th...
Abstract Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow limita...
Inhaled bronchodilators, including long-acting muscarinic receptor antagonists (LAMA) and long-actin...
Combining a long-acting β2-agonist (LABA) with a long-acting anti-muscarinic agent (LAMA) provides s...
Bronchodilators are the cornerstone of pharmacological management of COPD. For patients whose condit...
Despite the passionate debate over the use of β(2) -adrenoceptor agonists in the treatment of airway...
Josuel Ora,1 Angelo Coppola,2 Mario Cazzola,3 Luigino Calzetta,4 Paola Rogliani1,3 1Division of Resp...
Inhaled bronchodilators, including beta2-agonists and antimuscaric receptor antagonists, are the mai...
Inhaled bronchodilators, including beta2-agonists and antimuscaric receptor antagonists, are the mai...
An important step in simplifying asthma and chronic obstructive pulmonary disease (COPD) management ...
Abstract Chronic obstructive pulmonary disease (COPD) represents a significant cause of global morbi...
Introduction Long-acting muscarinic receptor antagonist (LAMA)/beta(2)-agonist (LABA) combinations r...